Inventor
OSBORNE DAVID W
64 patents
⚠️ This page may combine multiple inventors who share the name “OSBORNE DAVID W”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ARCUTIS BIOTHERAPEUTICS INC
10 patentsUS11819496B2Nov 21, 2023
Topical roflumilast formulation having improved delivery and plasma half-life
ARCUTIS BIOTHERAPEUTICS INC17 citations95
US11707454B2Jul 25, 2023
Topical roflumilast formulation having antifungal properties
ARCUTIS BIOTHERAPEUTICS INC16 citations88
US12005051B2Jun 11, 2024
Topical roflumilast formulation having improved delivery and plasma half life
ARCUTIS BIOTHERAPEUTICS INC4 citations86
US11992480B2May 28, 2024
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
ARCUTIS BIOTHERAPEUTICS INC8 citations82
US12310956B2May 27, 2025
Topical roflumilast formulation having improved delivery and plasma half-life
ARCUTIS BIOTHERAPEUTICS INC1 citations75
US12042558B2Jul 23, 2024
Method and formulation for improving roflumilast skin penetration lag time
ARCUTIS BIOTHERAPEUTICS INC3 citations75
US12042487B2Jul 23, 2024
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
ARCUTIS BIOTHERAPEUTICS INC4 citations75
US12005052B2Jun 11, 2024
Topical roflumilast formulation having improved delivery and plasma half-life
ARCUTIS BIOTHERAPEUTICS INC3 citations75
US11730740B2Aug 22, 2023
Laureth-4 containing topical formulations
ARCUTIS BIOTHERAPEUTICS INC2 citations73
US11628177B2Apr 18, 2023
Compositions and methods for deep dermal drug delivery
ARCUTIS BIOTHERAPEUTICS INC2 citations69
ARCUTIS INC
9 patentsUS10105354B1Oct 23, 2018
Inhibition of crystal growth of roflumilast
ARCUTIS INC23 citations98
US9907788B1Mar 6, 2018
Inhibition of crystal growth of roflumilast
ARCUTIS INC31 citations98
US9895359B1Feb 20, 2018
Inhibition of crystal growth of roflumilast
ARCUTIS INC35 citations98
US9884050B1Feb 6, 2018
Inhibition of crystal growth of roflumilast
ARCUTIS INC30 citations98
US11793796B2Oct 24, 2023
Inhibition of crystal growth of roflumilast
ARCUTIS INC18 citations94
US11534493B2Dec 27, 2022
Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
ARCUTIS INC19 citations94
US10940142B2Mar 9, 2021
Inhibition of crystal growth of roflumilast
ARCUTIS INC19 citations94
US10172841B2Jan 8, 2019
Inhibition of crystal growth of roflumilast
ARCUTIS INC21 citations94
US11129818B2Sep 28, 2021
Topical roflumilast formulation having improved delivery and plasma half life
ARCUTIS INC21 citations90
PROBST BRIAN HULLINGER
8 patentsUS8467178B2Jun 18, 2013
Tablet computer case and associated methods
PROBST BRIAN HULLINGER37 citations97
US8467183B2Jun 18, 2013
Tablet computer case and associated methods
PROBST BRIAN HULLINGER58 citations97
USD714790SOct 7, 2014
Tablet computer case
PROBST BRIAN HULLINGER22 citations92
US8472177B2Jun 25, 2013
Tablet computer case and associated methods
PROBST BRIAN HULLINGER16 citations92
US8472186B2Jun 25, 2013
Tablet computer case and associated methods
PROBST BRIAN HULLINGER28 citations92
US8467185B2Jun 18, 2013
Tablet computer case and associated methods
PROBST BRIAN HULLINGER12 citations92
US8467179B2Jun 18, 2013
Tablet computer case and associated methods
PROBST BRIAN HULLINGER22 citations92
USD679277SApr 2, 2013
Tablet computer case
PROBST BRIAN HULLINGER34 citations92
VIROTEX CORP
7 patentsUS5863560AJan 26, 1999
Compositions and methods for topical application of therapeutic agents
VIROTEX CORP107 citations99
US6159498ADec 12, 2000
Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces
VIROTEX CORP147 citations98
US5800832ASep 1, 1998
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
VIROTEX CORP274 citations98
US5955097ASep 21, 1999
Pharmaceutical preparation applicable to mucosal surfaces and body tissues
VIROTEX CORP90 citations97
US6620435B1Sep 16, 2003
Compositions for topical application of therapeutic agents
VIROTEX CORP21 citations93
US6290984B1Sep 18, 2001
Pharmaceutical preparation applicable to mucosal surfaces and body tissues
VIROTEX CORP34 citations92
US5762917AJun 9, 1998
Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring
VIROTEX CORP8 citations74
DOW PHARMACEUTICAL SCIENCES
2 patents(unassigned)
2 patentsCALGON VESTAL INC
2 patentsZAGG IP HOLDING CO INC
2 patentsCRUXCASE LLC
1 patentARIUS TWO INC
1 patentAXRIX LAB INC
1 patentATRIX LAB INC
1 patentVIROTEX CORP REEL FRAME
1 patentOSBORNE DAVID W
1 patentPILLAI RADHAKRISHNAN
1 patentRICE THOMAS E
1 patentShowing the top 50 of 64 patents by PatentIndex Score.